chufangao/CTO huggingface dataset:
Clinical trial NCT05000450: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Official title: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: Allogene Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated (Halted Prematurely)
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-06
Primary completion date: 2023-10-11
Completion date: 2023-10-11
Clinical trial NCT04310579: Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
Official title: Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
Sponsor: Food and Drug Administration (FDA) (FED)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 55.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-15
Primary completion date: 2021-05-25
Completion date: 2021-05-25
Plan to share individual participant data: YES
IPD sharing description: Plan is to make data from the study publicly available as part of a manuscript publication. In addition, the protocol and statistical analysis plan will be made available online at this site as well as any eventual publications.
Clinical trial NCT02355535: Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Official title: (STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Sponsor: Vanquish Oncology, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-02-28
Primary completion date: 2020-05-18
Completion date: 2020-05-18
Clinical trial NCT03489265: Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence
Official title: Treatment of Diarrhea-Associated Fecal Incontinence With Eluxadoline
Acronym: ELXDFI
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Difficult to recruit severely affected patients with fecal incontinence
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-30
Primary completion date: 2019-09-30
Completion date: 2020-03-31
Plan to share individual participant data: YES
IPD sharing description: Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB) and executes a data use/sharing agreement with the University of North Carolina.
IPD time frame: 9-36 months following publication of the study results.
IPD access criteria: Requester must have approval from an Institutional Review Board (IRB), Independent Ethics Committee (IED), or Research Ethics Board (REB), and requester has executed an acceptable data use/sharing agreement with UNC.
Clinical trial NCT03437746: Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study
Official title: Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study
Acronym: CORTICOLON
Sponsor: Centre Hospitalier Universitaire Dijon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: insufficient rate of inclusion
Enrollment: 78.0 (ACTUAL)
Start date: 2018-03-01
Primary completion date: 2021-09-30
Completion date: 2021-11-24
Clinical trial NCT05159128: A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants
Official title: A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-75105186 in Healthy Japanese Participants and a Single Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-75105186 in Healthy Chinese Participants
Sponsor: Janssen Pharmaceutical K.K. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Business Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-15
Primary completion date: 2022-04-02
Completion date: 2022-04-02
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT02049866: Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
Official title: Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-11-19
Primary completion date: 2020-03-31
Completion date: 2021-12-23
Plan to share individual participant data: NO
Clinical trial NCT05451017: The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers
Official title: The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers
Sponsor: Aelis Farma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study was initially paused due to a research hold of the institution. However, the study will not continue as the sample size of patients collected prior to the pause allowed for adequate data analysis of the study endpoints.
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-04
Primary completion date: 2023-06-26
Completion date: 2023-06-28
Plan to share individual participant data: NO
Clinical trial NCT03720990: Smith-Lemli-Opitz Syndrome and Cholic Acid
Official title: Smith-Lemli-Opitz Syndrome: A Pilot Study of Cholic Acid Supplementation
Sponsor: University of Nebraska (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-27
Primary completion date: 2022-08-30
Completion date: 2023-09-30
Baseline population: 12
Limitations and caveats: No limitations or caveats.
Plan to share individual participant data: YES
IPD sharing description: All data will be de-identified and submitted to the Database of Genotypes and Phenotypes (dbGAP), according to NIH regulations.
IPD time frame: Data will be available one year after completion of the study. Data will be available indefinitely.
IPD access criteria: Data will be made available to everyone.
Clinical trial NCT03621761: Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue
Official title: A Randomized Controlled Trial of Telephone-delivered Cognitive Behavioral-therapy, Modafinil, and Combination Therapy of Both Interventions for Fatigue in Multiple Sclerosis
Acronym: COMBO-MS
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 343.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-15
Primary completion date: 2021-08-24
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT05163756: To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient
Official title: A Multi-center, Double-blind, Randomized, Parallel, Active-controlled, Non-inferiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW1903 in Patients With Gastritis
Sponsor: Daewon Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 332.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-25
Primary completion date: 2021-04-27
Completion date: 2021-05-10
Plan to share individual participant data: NO
IPD sharing description: There is no plan for IPD.
Clinical trial NCT05289830: Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
Official title: A Phase II, Randomized, Double-blind, Trial Comparing Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-05
Primary completion date: 2023-08-27
Completion date: 2023-08-27
Plan to share individual participant data: YES
IPD sharing description: plan to publish the results
IPD time frame: 4 years to publication
Clinical trial NCT02743611: Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Official title: A Phase 1/2 Dose-Finding Study to Evaluate the Safety, Feasibility, and Activity of BPX-701, a Controllable PRAME T-Cell Receptor Therapy, in HLA-A2+ Subjects With AML, Previously Treated MDS, or Metastatic Uveal Melanoma
Sponsor: Bellicum Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: company decision
Enrollment: 4.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-04-14
Primary completion date: 2019-07-19
Completion date: 2020-07-19
Plan to share individual participant data: NO
Clinical trial NCT03635567: Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Official title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 617.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-25
Primary completion date: 2022-10-03
Completion date: 2024-06-04
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04411446: Cholecalciferol to Improve the Outcomes of COVID-19 Patients
Official title: Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients
Acronym: CARED
Sponsor: Vitamin D Study Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 218.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-11
Primary completion date: 2021-07-28
Completion date: 2021-07-28
Plan to share individual participant data: NO
Clinical trial NCT04304534: Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
Official title: Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group, Dose-finding Phase 2 Study to Evaluate the Efficacy and Safety of BAY 2433334 in Patients Following an Acute Myocardial Infarction
Acronym: PACIFIC-AMI
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 1601.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-06-17
Primary completion date: 2022-02-21
Completion date: 2022-02-21
Baseline population: FAS(Full data analysis)
Plan to share individual participant data: UNDECIDED
IPD sharing description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access.~As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT02962895: Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)
Official title: Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 192.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-06-27
Primary completion date: 2020-06-30
Completion date: 2021-09-23
Plan to share individual participant data: UNDECIDED
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02918968: Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Official title: A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in Castration-resistant Prostate Cancer (CRPC) Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus Androgen Deprivation Therapy (ADT)
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 206.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-02
Primary completion date: 2020-03-27
Completion date: 2020-03-27
Baseline population: Intent-to-Treat (ITT) population was defined as all participants randomized in this study.
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT02175212: Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
Official title: Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer.
Acronym: AADLPC
Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 362.0 (ACTUAL)
Number of arms: 2.0
Start date: 2005-11-30
Primary completion date: 2014-06-30
Completion date: 2020-09-24
Limitations and caveats: * Relatively short follow-up and low number of events.~* The lack of patient-reported outcomes.~* Our decision to include vascular events other than strictly cardiac events (e.g. the presence of CVA or thromboembolic disease).
Clinical trial NCT05054400: Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
Official title: Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: 0 participant accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-05
Primary completion date: 2023-08-29
Completion date: 2023-08-29
Clinical trial NCT05165849: A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
Official title: A Multicenter, Open-label, Phase I/Ⅱ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFS101A in Combination With Toripalimab Treating Patients With Advanced Solid Tumors
Sponsor: Genfleet Therapeutics (Shanghai) Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: sponsor decided to withdraw the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-04-30
Primary completion date: 2022-05-11
Completion date: 2022-05-11
Clinical trial NCT03393117: Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction
Official title: Prospective, Randomized, Blinded Comparison of Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Unilateral, Immediate Breast Reconstruction
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-30
Primary completion date: 2020-07-01
Completion date: 2020-07-01
Clinical trial NCT03994146: Remifentanil Tapering and Post-adenotonsillectomy Pain in Children
Official title: Remifentanil Tapering and Post-adenotonsillectomy Pain in Children: a Randomised, Placebo Controlled, Double Blind Study
Sponsor: University Hospital, Akershus (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Recruitment rate was not compatible with study completion
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-16
Primary completion date: 2023-08-18
Completion date: 2023-08-18
Plan to share individual participant data: YES
IPD sharing description: On request and following consultation with the Regional Ethics Committee and the Data Protection Officer at the host institution.
IPD time frame: The data will be available following completion of the study and analysis and publication by the investigating team.~There is no plan to time limit access to the data following this.
IPD access criteria: On request and following consultation with the Regional Ethics Committee and the Data Protection Officer at the host institution.
Clinical trial NCT03987451: A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
Official title: Investigation of Efficacy and Safety of Semaglutide s.c. Once-weekly Versus Placebo in Subjects With Non-alcoholic Steatohepatitis and Compensated Liver Cirrhosis
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 71.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-18
Primary completion date: 2021-04-22
Completion date: 2021-06-10
Baseline population: Full analysis set (FAS) included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT02987543: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
Official title: A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 387.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-02-06
Primary completion date: 2019-06-04
Completion date: 2023-02-15
Clinical trial NCT03061474: Nicotinamide as an Early Alzheimer's Disease Treatment
Official title: A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia
Acronym: NEAT
Sponsor: University of California, Irvine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-12
Primary completion date: 2022-08-30
Completion date: 2022-08-30
Plan to share individual participant data: YES
IPD sharing description: Data sharing is integral to the ADCS's mission to develop and execute innovative clinical trials focused on interventions that may prevent, delay, or treat the expression of Alzheimer's disease and related dementias. The ADCS is committed to sharing resources and tools, including data, biospecimens, trial designs, outcome and analysis measures following NIH guidelines.~DATA Sharing: The ADCS Data and Sample Sharing Committee (DSSC) grants access to de-identified data to individuals who complete the request process and agree to the conditions in an ADCS/UCSD Data Us Agreement (DUA). After approval and receipt of the fully executed DUA, applicants are authorized to acquire data. Non-compliance with the DUA, including the requirement to provide requested updates will jeopardize further access to data.
IPD time frame: 6 months after publication
IPD access criteria: Data requestors must complete ADCS data and sample sharing request form. Upon approval, requestors must complete a data use agreement prior to accessing data.
Clinical trial NCT03121963: Pain Management in Head and Neck Surgery Patients
Official title: Pain Management in Head and Neck Surgery Patients
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: This protocol was difficult to enroll into, and changes to personnel have made it difficult to main this study. Data collection was not completed and therefore, no data analysis was performed. The PI has made the decision to close this study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-10
Primary completion date: 2020-11-06
Completion date: 2021-11-06
Plan to share individual participant data: NO
IPD sharing description: There is no current plan to share individual participant data for this protocol.
Clinical trial NCT03038399: Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Official title: A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Sponsor: ReveraGen BioPharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 46.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-02-02
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Baseline population: Subjects entered this study in one of 4 dose level groups, but were allowed to escalate/de-escalate during the course of the study.